{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'Table 4.', 'Schedule of Assessments: Part 3 of Study BCX7353-302', 'Part 3', 'Assessment', 'Open-Label, Active Study Drug Administration', 'Week 60', 'Week 72', 'Week 84', 'Week 96', 'Visits every', 'Follow-up/', 'Day 421 6 days', 'Day 505 6 days', 'Day 589 6 days', 'Day 673 6 days', '12 weeks until', 'Early Termination', 'Visit', 'Week 144', 'Week 147 + 1 week', '6 days\u00b0', 'In-clinic evaluations', 'X', 'X', 'X', 'X', 'X', 'X', 'Telephone contactb', 'Subject weight9', 'X', 'X', 'X', 'X', 'X', 'X', 'Physical examination', 'X', 'X', 'X', 'X', 'X', 'X', 'Urine pregnancy test', 'X', 'Xd', 'Xd', 'X', 'X', 'X', 'Vital signse', 'X', 'X', 'X', 'X', 'X', 'X', 'Safety laboratory evaluations', 'X', 'X', 'X', 'X', 'X', 'X', 'Troponin I and Troponin T', 'X', 'X', 'X', 'X', 'X', 'X', 'NGAL', 'X', 'X', 'X', 'X', 'X', 'X', 'CK-MB', 'X', 'X', 'X', 'X', 'X', 'X', 'Urinalysis\u00b9', 'X', 'X', 'X', 'X', 'X', 'X', '12-lead ECGg', 'X', 'X', 'X', 'X', 'X', 'X', 'EQ-5D-5Lb,', 'X', 'X', 'X', 'X', 'X', 'AE-QoL, TSQM, WPAI,', 'X', 'X', 'X', 'X', 'X', 'long-term experience survey1,p', 'Concomitant medications', 'AEs', \"Diary instruction/review'\", 'X', 'X', 'X', 'X', 'X', 'X', 'Diary daily completion', 'Study drug dosing\u00b9', 'Study drug accountability/', 'dispensing', 'X', 'X', 'X', 'X', 'X', 'X', 'Plasma for PK analysis\"', 'Xm', 'Plasma for kallikrein', 'Xm', 'inhibition', 'Abbreviations: AE = adverse event; AE-QoL = Angioedema Quality of Life; CK-MB = creatine kinase MB isoenzyme; CRF = case report form;', 'ECG = electrocardiogram; EQ-5D-5L = EuroQoL 5-dimensional, 5-level questionnaire; NGAL = neutrophil gelatinase-associated lipocalin;', \"PD = pharmacodynamic; PK = pharmacokinetic; QoL = quality of life; QTcF = QT interval corrected using Fridericia's method; TSQM = Treatment Satisfaction\", 'Questionnaire for Medication; WPAI = Work Productivity and Activity Index.', '60']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'a', 'Period 3 study drug is to be initiated on Day 337, the day of the Week 48 visit.', 'b', 'The', 'Investigator (or designee) must call and talk to the subject during Weeks 52, 56, 64, 68, 76, 80, 88, and 92; alternative forms of interactive', 'communication such as returned email and cellular text correspondence are acceptable. During all calls, the Investigator (or designee) will assess the', \"subject's overall wellbeing, and proper recording of attack details (if applicable).\", 'c', 'Abbreviated physical examinations targeted to signs and symptoms will be performed at post-baseline visits.', 'd', 'At clinic visits, sites in Europe will dispense urinary pregnancy tests to subjects who are women of childbearing potential. These will be performed by the', 'subject at home at monthly intervals between study visits.', 'e', 'To include blood pressure and pulse rate. Prior to obtaining vital signs, subjects should rest in a supine position for at least 5 minutes.', 'f', 'Table 5 lists parameters to be assessed.', 'g', 'ECGs may be single assessments. Prior to obtaining an ECG, subjects should rest quietly in a supine position for at least 10 minutes. An ECG should be', 'repeated for a change from baseline in QTcF > 60 msec or a QTcF interval > 500 msec.', 'h', 'Two EQ-5D-5L assessments will be administered at Weeks 60, 72, 84, and 96. The subject will fill out the first EQ-5D-5L to describe their current health', 'state today as instructed per the instrument. The subject will also fill out a second EQ-5D-5L based on a recollection of their health state during an average', 'attack that they experienced since the last study visit. If the subject has not had an attack since their last study visit, the subject is not required to fill out the', 'second, attack-related EQ-5D-5L. After Week 96, the EQ-5D-5L will be administered every 24 weeks (Weeks 120 and 144) and at end-of-study visit.', 'i', 'Where possible, QoL and health outcome questionnaires should be collected as the first assessments at a visit.', 'j', 'Any issues (including mediocre or poor compliance) warranting diary re-education should occur on an as-needed basis.', 'k', \"Any time the diary is in the subject's possession after Week 48 the subject will enter HAE attacks and relevant details at least once per day. No dosing\", 'information will be collected in in subject diaries in Part 3.', '1', 'Study drug should be taken at approximately the same time each day, with whichever meal is typically the largest of the day. Subjects are not required to', 'take their doses at clinic visits.', 'm', 'Early termination visit only (if occurring during dosing phase).', 'n', 'PK and PD blood samples will be drawn on all subjects with no particular relationship to the timing of study drug dosing. The Investigator (or designee)', 'must ensure that the time of the last dose prior to PK and PD draw is recorded in the CRF. Blood sample for PK is not required at the follow-up visit; blood', 'sample is only required at an early termination visit occurring before Week 48.', 'Up to 144 weeks or until another mechanism is available to provide drug to the subject, or until the Sponsor discontinues development of the product for the', 'prevention of angioedema attacks, whichever comes first.', 'p', 'After Week 96, the TSQM and WPAI will be administered every 24 weeks (Weeks 120 and 144). Beginning at Week 96, the subject long-term experience', 'survey will be administered every 24 weeks (96, 120, and 144).', 'q', 'Adolescent subjects will also have height measured at Weeks 96 and 144.', '61']\n\n###\n\n", "completion": "END"}